EP1051993A2 — 5HT1 receptor agonists and either a cox-2 inhibitor or NSAID for the treatment of migraine
Assigned to Pfizer Products Inc · Expires 2000-11-15 · 26y expired
What this patent protects
The present invention relates to a method of treating migraine in a mammal, including a human, by administering to the mammal a 5HT 1 receptor agonist in combination with either a cyclooxygenase-2 (COX-2) inhibitor or a nonsteroidal antiinflammatory drug (NSAID). It also relates…
USPTO Abstract
The present invention relates to a method of treating migraine in a mammal, including a human, by administering to the mammal a 5HT 1 receptor agonist in combination with either a cyclooxygenase-2 (COX-2) inhibitor or a nonsteroidal antiinflammatory drug (NSAID). It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT 1 receptor agonist with either a cyclooxygenase-2 (COX-2) inhibitor or a nonsteroidal antiinflammatory drug (NSAID).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.